DNA X, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $58.3M | $93.6M | $69.8M | $54.6M | $64.0M | $116.3M |
| Cost of Revenue | — | — | $48.4M | $74.3M | $58.2M | $48.2M | $48.8M | $81.7M |
| Gross Profit | — | — | $9.9M | $19.3M | $11.6M | $6.4M | $15.2M | $34.5M |
| Gross Margin | — | — | 17.0% | 20.6% | 16.6% | 11.8% | 23.8% | 29.7% |
| Operating Expenses | ||||||||
| Research & Development | — | — | $14.2M | $1.8M | $8.0M | $17.7M | $16.2M | $26.1M |
| SG&A Expense | — | $5.4M | $3.1M | $8.3M | $10.7M | $10.3M | $9.8M | $15.1M |
| Operating Income | — | $-5.4M | $-3.1M | $513.0K | $-14.3M | $-38.0M | $-29.3M | $-22.4M |
| Operating Margin | — | — | -5.3% | 0.5% | -20.5% | -69.6% | -45.7% | -19.3% |
| Interest Expense | — | $945.0K | — | — | $97.0K | — | — | — |
| Pretax Income | — | $-8.0M | $-2.9M | $284.0K | $-13.9M | $-38.5M | $-30.5M | $-24.4M |
| Income Tax Expense | — | $-1.1M | $226.0K | $374.0K | $184.0K | $167.0K | $-521.0K | $1.4M |
| Net Income | — | $-20.7M | $-33.6M | $-90.0K | $-14.1M | $-38.6M | $-29.9M | $-25.8M |
| Net Margin | — | — | -57.7% | -0.1% | -20.2% | -70.8% | -46.8% | -22.2% |
| EPS (Basic) | — | $-28.58 | $-42.79 | $-0.01 | $-0.16 | $-0.45 | $-0.72 | $-0.15 |
| EPS (Diluted) | — | $-28.58 | $-42.79 | $-0.01 | $-0.16 | $-0.45 | $-0.72 | $-0.15 |
| Shares Outstanding (Basic) | 1.5M | 722.7K | 786.4K | 12.9M | 86.7M | 85.2M | 59.7M | 183.9M |
| Shares Outstanding (Diluted) | 1.5M | 722.7K | 786.4K | 12.9M | 86.7M | 85.2M | 59.7M | 183.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |